longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

04:39 ETRegeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN

prnewswire
Aug 21, 2026 at 08:40 AM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

The DJS Law Group is reminding investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) for alleged securities law violations under Sections 10(b) and 20(a). The suit claims the company made false statements regarding its Phase III Fianlimab-Libtayo Study results between August 1, 2025, and May 15, 2026. Shareholders who suffered losses during this period are encouraged to contact the firm by September 14, 2026, to discuss potential lead plaintiff appointments or recovery.

, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: August 1, 2025 to May 15, 2026

DEADLINE: September 14, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. The Company gave investors the impression its Phase III Fianlimab-Libtayo Study showed signs of success and minimized risks presented by the study. The Company's study ultimately failed to achieve its primary endpoint in a statistically significant manner. Based on these facts, Regeneron's public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

Eastchester, NY 10709

Phone: 914-206-9742

Email: [email protected]

SOURCE DJS Law Group LLP

Login to unlock1,511characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Recommended Readings

  • Sep 9, 2026 at 04:53 AMUS to ban Canadian motorcycle, dairy, alcohol imports as trade war sizzles
  • Sep 8, 2026 at 12:14 PMAI-era DCI: Beyond the chip, compete as a network. Is there a China play?
  • Jun 4, 2025 at 06:49 AMGoldman Sachs updates ASCO latest clinical progress, three US pharmaceutical companies receive "Buy" rating
Regeneron Pharma

Regeneron Pharma

REGN.US

Open

--

High

--

Low

--

Prev Close

--

P/ETTM

--

Market Cap

--

LongbridgeAI